Suppr超能文献

症状发作至球囊时间与首次接受经皮冠状动脉介入治疗的 STEMI 后 7 年内的死亡率。

Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention.

机构信息

Department of Cardiology, Ospedali del Tigullio, Lavagna 16033, Italy.

出版信息

Heart. 2012 Dec;98(23):1738-42. doi: 10.1136/heartjnl-2012-302536. Epub 2012 Sep 28.

Abstract

OBJECTIVE

To evaluate the consequence of treatment delay of primary percutaneous coronary intervention (PPCI) on long-term survival.

BACKGROUND

Network organisation based on early recognition, shortening prehospital time delays and procedural delays is the cornerstone of optimal clinical results in the acute phase of ST-segment elevation myocardial infarction (STEMI). Nevertheless, the evidence of a relationship between symptom onset-to-balloon time and mortality is weak, and few long-term data are available. SETTING AND MEASURES: In this single-centre observational follow-up study, we evaluated the long-term survival of 790 consecutive STEMI patients (mean age 68 ± 13 years; 73% males) undergoing PPCI ≤ 12 h from symptom onset, or 12-36 h in the case of persistence of symptoms or hemodynamic instability.

RESULTS

The median (IQR) treatment delay, defined as the time from symptom onset to reperfusion, was 180 min (120;310), fairly balanced between patient delay (80 min (40;140)) and system delay (80 min (60-114)). Patients with a treatment delay <180 min displayed lower mortality at 1, 3, 5 and 7 years (12%, 17%, 22% and 26%, respectively) than those with a treatment delay >180 min (15%, 24%, 28% and 37%, respectively). The HR was 0.7 (95% CI 0.5 to 0.9). On univariate and stepwise multiple regression analysis, field triage and transportation (p=0.0001), shorter distance from hospital (p=0.02) and male gender (p=0.02), but not clinical variables, were independent predictors of shorter treatment delay.

CONCLUSIONS

Shorter symptom onset-to-balloon time predicts long-term lower mortality in STEMI patients treated with PPCI. Our findings emphasise the need to minimise any component of treatment delay.

摘要

目的

评估直接经皮冠状动脉介入治疗(PPCI)治疗延迟对长期生存的影响。

背景

基于早期识别、缩短院前时间延迟和操作延迟的网络组织是 ST 段抬高型心肌梗死(STEMI)急性期获得最佳临床效果的基石。然而,症状发作至球囊时间与死亡率之间的关系证据不足,且可用的长期数据有限。

地点和措施

在这项单中心观察性随访研究中,我们评估了 790 例连续 STEMI 患者(平均年龄 68 ± 13 岁;73%为男性)的长期生存情况,这些患者在症状发作后 12 小时内或在症状持续或血流动力学不稳定的情况下 12-36 小时内行 PPCI。

结果

中位(IQR)治疗延迟(定义为从症状发作到再灌注的时间)为 180 分钟(120;310),在患者延迟(80 分钟(40;140))和系统延迟(80 分钟(60-114))之间基本平衡。治疗延迟<180 分钟的患者在 1、3、5 和 7 年时的死亡率较低(分别为 12%、17%、22%和 26%),而治疗延迟>180 分钟的患者的死亡率较高(分别为 15%、24%、28%和 37%)。风险比为 0.7(95%置信区间 0.5 至 0.9)。在单变量和逐步多变量回归分析中,现场分诊和转运(p=0.0001)、与医院的距离较短(p=0.02)和男性(p=0.02),而不是临床变量,是治疗延迟更短的独立预测因素。

结论

STEMI 患者接受 PPCI 治疗时,症状发作至球囊时间越短,长期死亡率越低。我们的研究结果强调了需要尽量减少治疗延迟的任何组成部分。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验